Status:
UNKNOWN
We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.
Lead Sponsor:
Xiangcheng Zhang
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Brief Summary
The investigators selected patients diagnosed with sepsis who were admitted to the Intensive Care Unit (ICU) of Huai'an First People's Hospital between June 2022 and December 2023, as well as healthy ...
Eligibility Criteria
Inclusion
- Patients with sepsis admitted to the ICU.
Exclusion
- Under 18 years old;
- History of chronic kidney disease;
- Recipients of organ transplantation within the past year;
- Patients or their families could not give informed consent.
Key Trial Info
Start Date :
July 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06001294
Start Date
July 3 2022
End Date
December 31 2023
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Critical Care Medicine, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
Huaian, Jiangsu, China, 223001